ABNORMAL PROCESSING OF THE HUMAN CHOLECYSTOKININ RECEPTOR GENE IN ASSOCIATION WITH GALLSTONES AND OBESITY

Citation
Lj. Miller et al., ABNORMAL PROCESSING OF THE HUMAN CHOLECYSTOKININ RECEPTOR GENE IN ASSOCIATION WITH GALLSTONES AND OBESITY, Gastroenterology, 109(4), 1995, pp. 1375-1380
Citations number
19
Categorie Soggetti
Gastroenterology & Hepatology
Journal title
ISSN journal
00165085
Volume
109
Issue
4
Year of publication
1995
Pages
1375 - 1380
Database
ISI
SICI code
0016-5085(1995)109:4<1375:APOTHC>2.0.ZU;2-U
Abstract
Background & Aims: Cholesterol gallstone disease and obesity are often associated and share the potential, yet unreported, common etiology o f cholecystokinin (CCK) dysfunction. While cloning the human CCK-A rec eptor complementary DNA (cDNA), we found predominance of a 262-base pa ir coding region deletion in a cDNA library prepared from a patient wi th this phenotype. The aim of this study was to determine the abundanc e, functional significance, and mechanism for generating this gene pro duct. Methods: Relative abundance of CCK receptor gene products was de termined using polymerase chain reaction and hybridization analysis. C onstructs were expressed in COS cells and studied for radioligand bind ing and intracellular calcium responses. A human genomic clone for thi s receptor was sequenced, and the critical regions were compared with those of the patient. Results: Ninety-three percent of the patient's C CK receptor transcripts contained the 262-base pair deletion, whereas only 1.5% +/- 0.9% of control patients had the deletion. This encoded a receptor that did not bind or signal. The deletion corresponded with the third exon; however, this sequence and Ranking introns were norma l in the patient. Conclusions: Abnormality of processing an apparently normal CCK receptor gene yields the predominant product with an absen t third exon and encoding a nonfunctional receptor, probably reflectin g a defective trans-acting splicing factor. An atypical lariat region in the third intron may explain the presence of small amounts of this product in control patients.